Novation Companies, Inc. (NOVC)

0.05
OTC Markets
Prev Close 0.05
Day Low/High 0.04 / 0.05
52 Wk Low/High 0.01 / 0.10
Exchange OTC Markets
Shares Outstanding 101.30B
Market Cap 4.96M
Div & Yield N.A. (N.A)

Latest News

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

Middlebrook Pharma still has some upside left.

Novacea Reins In R&D

Novacea Reins In R&D

The biotech company halts or slows some development spending to preserve capital.

Novacea Posts Narrower Loss

Novacea Posts Narrower Loss

Third-quarter revenue climbs on a reimbursement from Schering-Plough.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Novacea falls.

Novacea Halts Phase III Study

Novacea Halts Phase III Study

An imbalance of death rates prompts it to end the trial of lead investigational cancer therapy Ascentar.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

NPS Pharma falls on disappointing phase III study results.

Wednesday's Health Winners & Losers

Emergent BioSolutions gains on a $448 million contract for its anthrax vaccine BioThrax.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

This week, questions on Vertex Pharmaceuticals, Novacea and more.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Bayer climbs on takeover rumors.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

The mailbag returns with questions about Northwest Biotherapeutics, Flamel and, of course, Dendreon.

You Ask, Cramer Answers

Jim Cramer answers questions on Valero, Baidu and more.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Neose Technologies climbs on positive drug data.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

Novacea's fair value, company-to-watch Amicus Therapeutics and just a little more Dendreon.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

The Novacea story, Millenium Pharmaceuticals potential and Satraplatin's impact.

Choppy Conditions

This environment offered good opportunities for day trades but was an invitation to lose money on everything else.

Stockpickr Lists: Peregine

Stockpickr Lists: Peregine

Wachovia buys AG Edwards, and Peregine collaborates with Dios.

Thursday's Small-Cap Winners & Losers

Thursday's Small-Cap Winners & Losers

OccuLogix climbs on buyout news.

Stockpickr Lists: Novacea

Stockpickr Lists: Novacea

Novacea soars after a deal with fellow drugmaker Schering-Plough.

A Run for the Record Books

A Run for the Record Books

Early weakness is met by hearty buying after the FOMC minutes. Gallatin's Mark Keller talks bubbles vs. bull markets. Plus, 'Should I Buy It?'

A Run for the Record Books

Early weakness is met by hearty buying after the FOMC minutes. Gallatin's Mark Keller talks private equity, plus 'Should I Buy It?'.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Biogen climbs on news of a $3 billion share buyback.

Novacea Soars on Schering Deal

Novacea Soars on Schering Deal

Shares of the drugmaker double on news of a development and marketing deal for its Asentar.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Johnson & Johnson's rise on better-than-expected earnings boosted health care stocks.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Novacea slips on an executive change.

Monday's Small-Cap Winners & Losers

Monday's Small-Cap Winners & Losers

Novacea climbs.

From Our Partners